Given the well-established cardiovascular benefits of novel antidiabetic agents, such as glucagon-like peptide-1 receptor agonists, future studies are warranted to assess whether these therapies can modify the effects of comprehensive risk factor control on mortality in T2D. The gene discussed is GLP1R; the disease is type 2 diabetes mellitus.